Video

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Thomas Hutson, DO, PharmD, director, Urologic Oncology Program, co-chair, Urologic Cancer Research and Treatment Center, Baylor University Medical Center, professor of medicine, Texas A&M College of Medicine, discusses remaining questions regarding the durability of response to immunotherapy in patients with renal cell carcinoma (RCC).

Of particular interest at the 2020 SITC Virtual Congress will be data that are focused on modifying immune responses with T-cell trafficking and classifying tumors based on immune signatures, Hutson says.

Additionally, developing a greater understanding of whether memory T cells and CTLA-4 play key roles in eliciting long-term durable complete or partial responses is needed in RCC, says Hutson.

Other ongoing trials are attempting to determine the effect of patient characteristics on response durability, Hutson explains. In RCC, classifying tumors to enrich a particular patient population that is likely to derive benefit from immunotherapy may be an effective strategy to help answer this question.

Finally, ongoing research efforts are underway to understand how altering the tumor microenvironment could make a patient more responsive to immunotherapy, concludes Hutson.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity